Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized myasthenia gravis. It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition. In July 2024, it was approved by Health Canada for the same indication.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Zilucoplan
Drug Overview
What is Zilucoplan?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Zilucoplan is a chemical substance that may be handled in pharmaceutical and chemical manufacturing. The precise toxicological profile and occupational exposure considerations should be established from reliable substance-specific evidence rather than inferred from the name alone. Reviewing the available data and intended handling conditions can support a documented assessment of worker protection and potential cross-contamination risk.
A PDE or ADE sets a health-based limit on daily exposure to Zilucoplan from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
A toxicological assessment of Zilucoplan reviews the available evidence to characterize potential hazards and support proportionate risk management. The findings can inform health-based exposure limits, handling practices, containment measures, and cross-contamination controls. The conclusions should reflect the quality and relevance of the available data, clearly document uncertainties, and avoid treating data gaps as evidence that a substance is safe.
The physical form in which Zilucoplan is handled may affect the potential for exposure and the controls needed in the workplace. Powders, liquids, solutions, and other forms can behave differently during dispensing, transfer, sampling, or cleaning. The occupational assessment should consider the actual process and potential exposure routes, while keeping the toxicological hazard assessment distinct from the practical evaluation of exposure likelihood.
Where Zilucoplan is a medicinal substance and suitable therapeutic-dose information is available, that information may provide context for the assessment but should not automatically determine a PDE or OEL. The assessor must consider the relevant toxicological endpoint, route, population, data quality, and intended exposure scenario. Any use of pharmacological or clinical information should be scientifically justified and documented alongside the other relevant evidence.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Zilucoplan in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
A report for Zilucoplan should describe the assessment scope, the evidence reviewed, the scientific rationale, relevant calculations, uncertainty factors where applicable, assumptions, and the resulting conclusions or recommendations. It should identify important data gaps and explain how they affect interpretation. The content should be tailored to the substance and intended use, with clear documentation that allows technical reviewers to follow the reasoning.
A scientifically justified PDE for Zilucoplan can help establish a health-based reference point for assessing potential residue carryover between products processed with shared equipment. Cleaning validation teams can use the assessment alongside equipment, process, analytical, and product-specific considerations to establish appropriate acceptance criteria. The PDE does not replace the full cleaning-risk assessment, and its use should follow applicable procedures and regulatory expectations.
An OEL report for Zilucoplan can provide a scientific benchmark for evaluating workplace exposure when a suitable limit can be established. Used alongside exposure monitoring, engineering controls, suitable work practices, and appropriate protective equipment, it can help guide risk management during dispensing, transfer, processing, sampling, and cleaning. The OEL should be considered within a broader occupational risk assessment rather than as a substitute for controls.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Zilucoplan to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
